Genomic technology company Biofidelity has announced the launch of ASPYRE-Lung reagents (RUO) for research use, marking its second product launch this year, with the aim of providing simple
Cambridge, UK-based Biofidelity has raised $12 million in first-round funding for its cancer diagnosis platform, which can detect mutations quicker than current approaches
Endeavor BioMedicines has completed a third round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.